UK Industry Warns Against Post-Brexit Regulatory Divergence
The MHRA Could Help Design ‘Gold Standard’ Practices
Executive Summary
The UK must maintain a competitive regulatory framework at home, and its medicines agency should play a part in influencing international regulatory policy alongside other national and global organizations, says a new report from the ABPI.
You may also be interested in...
New UK Drug Applications At ‘Sustained Levels’ Post-Brexit
The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.
UK Life Science Industry Presses Government On Need For Continued Regulatory Alignment Post-Brexit
UK industry figures have outlined the importance of continuing regulatory alignment in the life sciences area after Brexit, following the latest meeting of the UK EU Life Sciences Steering Group. The UK government may be listening, but what positions will the other 27 member states take?
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.